Compare Vanguard Information Technology Index Fund ETF (VGT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 10× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VGT | ZBH | |
|---|---|---|
Market Cap | $170.20B | $16.95B |
Volume | 5,132,883 | 2,505,240 |
52-Week High | $129.79 | $103.98 |
52-Week Low | $83.59 | $79.58 |
Typical Hold Time | 129 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.25, down 1.64% on the day but maintains a bullish technical outlook with strong moving average support. The ETF's concentration in leading technology companies like Nvidia, Apple, and Microsoft provides exposure to AI and cloud computing growth trends. Recent articles highlight VGT's historical performance of over 17% annual returns over the past two decades.
The outlook remains positive given technology sector momentum and VGT's low expense ratio advantage. Key risks include sector concentration and potential AI market slowdowns. Current technical positioning near pivot point resistance at $128 suggests potential for breakout if momentum continues.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
